STOCK TITAN

Assembly Biosciences, Inc - ASMB STOCK NEWS

Welcome to our dedicated page for Assembly Biosciences news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Biosciences stock.

Assembly Biosciences, Inc. (NASDAQ: ASMB) is a public clinical-stage biotechnology company dedicated to advancing innovative therapies for serious viral diseases. The company focuses on two key platform programs: the treatment of Hepatitis B virus (HBV) infection and the development of novel oral live biotherapeutics for disorders associated with the microbiome.

In the HBV program, Assembly Biosciences is pioneering a new class of oral therapeutics aimed at increasing cure rates for patients with chronic HBV. The company has developed several drug candidates that inhibit various steps in the HBV lifecycle, including novel core protein allosteric modulators (CpAMs). These small molecules target and modulate the HBV core protein, a crucial component in the virus's replication process.

The microbiome program is designed to address diseases linked to dysbiosis, an imbalance in the microbial community of the gut. Assembly Biosciences employs a robust strain identification and selection process, methods for strain isolation and growth under Good Manufacturing Practices (GMP), and a patent-pending delivery system known as GEMICEL®. This system ensures targeted delivery of live biotherapeutics to specific areas in the gastrointestinal tract.

Recent achievements for Assembly Biosciences include a long-term partnership with Gilead Sciences to accelerate the development of their antiviral pipeline. This collaboration is expected to enhance the company's financial and scientific resources, positioning them to achieve critical milestones and deliver innovative treatments to patients.

Financial results for the third quarter of 2023 highlighted the company's ongoing progress, including the advancement of multiple antiviral candidates targeting herpesviruses, HBV, and hepatitis delta virus (HDV). Assembly Biosciences also announced leadership enhancements, including the appointment of Dr. Anuj Gaggar as Chief Medical Officer.

Looking ahead, Assembly Biosciences plans to have four candidates in clinical studies by the end of 2024. These include the initiation of trials for ABI-5366, a long-acting herpes simplex virus helicase-primase inhibitor, and the development of ABI-6250, an orally bioavailable small molecule for treating chronic HDV.

For more information, visit assemblybio.com.

Rhea-AI Summary

Assembly Biosciences, Inc. (Nasdaq: ASMB) has selected a new core inhibitor candidate, ABI-4334, optimized for potency, to advance into clinical development targeting hepatitis B virus (HBV). The company is executing preclinical work with plans to initiate clinical studies in 2022. ABI-4334 shows promising preclinical results, including single-digit nanomolar potency against new virus production and cccDNA formation. The candidate demonstrates pan-genotypic activity, an improved resistance profile, and favorable pharmacokinetics, aiming to offer a finite and curative HBV therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
-
Rhea-AI Summary

Assembly Biosciences (ASMB) reported its Q2 2021 financial results, highlighting a cash position of $199.1 million. However, revenues plummeted to $0, down from $39.4 million in Q2 2020, due to the termination of its microbiome collaboration with Allergan. R&D expenses decreased to $16.7 million from $23.3 million, while general and administrative costs fell to $6.9 million from $9.5 million. The net loss was $23.6 million, or $0.55 per share, compared to net income of $7.3 million, or $0.21 per share, in the previous year. The company aims to advance its HBV clinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
-
Rhea-AI Summary

Assembly Biosciences, Inc. (Nasdaq: ASMB) announced the promotions of Jason Okazaki to Chief Operating Officer and Michael Samar to Chief Financial Officer. Okazaki, with 20 years of business and legal experience, has been with Assembly Bio since 2020, while Samar has over 20 years in finance and operations since joining the company in 2017. CEO John McHutchison praised their contributions toward achieving long-term objectives in developing therapies targeted at hepatitis B virus (HBV). The company aims to provide curative treatments for the 270 million HBV-infected individuals globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
management
Rhea-AI Summary

Assembly Biosciences Appoints Dr. Michael Houghton to Board

Assembly Biosciences, Inc. (Nasdaq: ASMB) has appointed Sir Michael Houghton, PhD, a Nobel Prize-winning virologist, to its board of directors. Dr. Houghton, renowned for discovering the hepatitis C virus, brings over 40 years of drug development experience. His expertise is expected to enhance Assembly Bio's efforts towards finite and curative therapies for hepatitis B virus (HBV), targeting over 250 million individuals globally. CEO John McHutchison emphasized the potential impact of Dr. Houghton’s insights on the company's innovative therapeutic pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
management
-
Rhea-AI Summary

Assembly Biosciences (ASMB), a clinical-stage biotechnology company, announced the grant of stock options to three new employees for a total of 21,520 shares at an exercise price of $3.82. The options have a ten-year term and will vest over four years. This grant is part of Assembly Bio's 2020 Inducement Award Plan and aims to support the hiring of new talent as part of their commitment to developing innovative therapeutics for hepatitis B virus (HBV). The approval was made by the Compensation Committee, consisting of independent directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
none
-
Rhea-AI Summary

Assembly Biosciences (Nasdaq: ASMB) presented data from its core inhibitor programs during the International Liver Congress™ 2021, focusing on hepatitis B virus (HBV) therapies.

CEO John McHutchison highlighted the promising efficacy of their lead candidate, vebicorvir (VBR), alongside next-generation candidates ABI-H2158 and ABI-H3733. These drugs aim for deeper virologic suppression in HBV patients. The data showed significant plasma concentrations above effective levels, indicating potential improved outcomes. However, no sustained virologic response was observed in patients stopping VBR treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
none
Rhea-AI Summary

Assembly Biosciences (Nasdaq: ASMB) announced that three abstracts related to their hepatitis B virus (HBV) therapeutics will be presented at the International Liver Congress™ 2021 from June 23-26, 2021. The company will showcase findings on its core inhibitor programs, vebicorvir (VBR), ABI-H2158, and ABI-H3733. Key presentations include an oral discussion on the enhanced potency of the next-generation inhibitors and two posters revealing resistance data and treatment response following therapy discontinuation.

Chronic HBV affects approximately 270 million people worldwide, highlighting the urgent need for effective treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.85%
Tags
conferences
-
Rhea-AI Summary

Assembly Biosciences (Nasdaq: ASMB) announced stock options granted to six new employees, totaling 106,520 shares at an exercise price of $4.03, the closing price on June 1, 2021. These options serve as inducements for employment and have a ten-year term with a four-year vesting schedule. The options were approved by the Compensation Committee as per Nasdaq regulations and fall under the 2017 Inducement Award Plan. Assembly Bio focuses on innovative therapeutics for hepatitis B, aiming to develop curative therapies for the 270 million global patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
none
-
Rhea-AI Summary

Assembly Biosciences, Inc. (Nasdaq: ASMB) has appointed Dr. Lisa Johnson-Pratt to its board of directors. With over 20 years in drug development, she previously led commercial strategies at Ionis Pharmaceuticals and GlaxoSmithKline. Dr. Johnson-Pratt will contribute her expertise in clinical programs and commercialization as Assembly Bio advances its hepatitis B virus (HBV) treatment pipeline. Her appointment comes as the company aims to provide innovative, curative therapies for the 270 million individuals suffering from HBV globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
management
Rhea-AI Summary

Assembly Biosciences, Inc. (ASMB) announced the granting of stock options to three new employees, totaling 25,000 shares at an exercise price of $4.16 per share. This measure is designed to attract talent, with options vesting over four years and subject to continued employment. The options were approved by the Compensation Committee, adhering to Nasdaq Listing Rule 5635(c)(4). Assembly Bio is focused on innovative therapies for hepatitis B virus (HBV), aiming to provide curative solutions to the estimated 270 million people affected globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.94%
Tags
none

FAQ

What is the current stock price of Assembly Biosciences (ASMB)?

The current stock price of Assembly Biosciences (ASMB) is $16.92 as of October 31, 2024.

What is the market cap of Assembly Biosciences (ASMB)?

The market cap of Assembly Biosciences (ASMB) is approximately 107.4M.

What does Assembly Biosciences, Inc. specialize in?

Assembly Biosciences specializes in developing innovative therapies for serious viral diseases, focusing on HBV and microbiome-related disorders.

What are the main programs of Assembly Biosciences?

The main programs are an HBV program for treating hepatitis B virus infection and a microbiome program developing novel oral live biotherapeutics.

What is the HBV program at Assembly Biosciences?

The HBV program aims to increase cure rates for chronic HBV patients using a new class of oral therapeutics that target various steps in the HBV lifecycle.

What is the microbiome program at Assembly Biosciences?

The microbiome program focuses on developing live biotherapeutics for diseases associated with the microbiome, using a targeted delivery system called GEMICEL®.

What recent achievements has Assembly Biosciences made?

Recent achievements include a partnership with Gilead Sciences, advancements in multiple antiviral candidates, and leadership enhancements such as the appointment of Dr. Anuj Gaggar as CMO.

What are the anticipated milestones for Assembly Biosciences in 2024?

Assembly Biosciences plans to have four clinical candidates in studies, including trials for ABI-5366 for herpes and ABI-6250 for chronic HDV.

How does Assembly Biosciences' GEMICEL® delivery system work?

GEMICEL® is a patent-pending system designed to deliver live biotherapeutics to specific regions of the gastrointestinal tract effectively.

What is the significance of the partnership with Gilead Sciences?

The partnership with Gilead Sciences provides Assembly Biosciences with financial and scientific resources to accelerate their antiviral pipeline and reach critical milestones.

Who is the CEO of Assembly Biosciences?

Jason Okazaki is the CEO and President of Assembly Biosciences.

Where can I find more information about Assembly Biosciences?

More information can be found on their official website at www.assemblybio.com.

Assembly Biosciences, Inc

Nasdaq:ASMB

ASMB Rankings

ASMB Stock Data

107.40M
6.35M
31.62%
18.57%
0.26%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO